Arca Biopharma Company Profile (NASDAQ:ABIO)

About Arca Biopharma (NASDAQ:ABIO)

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Symbol: NASDAQ:ABIO
CUSIP: N/A
Web: www.arcabiopharma.com

Capitalization:

Market Cap: $21.46 million
Outstanding Shares: 9,130,000

Average Prices:

50 Day Moving Avg: $2.45
200 Day Moving Avg: $2.51
52 Week Range: $2.15 - $3.93

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -1.97
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: N/A
Price / Sales: N/A
Book Value: $2.44 per share
Price / Book: 0.96

Profitability:

EBIDTA: ($16,290,000.00)
Return on Equity: -47.28%
Return on Assets: -44.61%

Debt:

Current Ratio: 11.06%
Quick Ratio: 11.06%

Misc:

Average Volume: 25,543 shs.
Beta: 2.16
Short Ratio: 3.5

Frequently Asked Questions for Arca Biopharma (NASDAQ:ABIO)

What is Arca Biopharma's stock symbol?

Arca Biopharma trades on the NASDAQ under the ticker symbol "ABIO."

How were Arca Biopharma's earnings last quarter?

Arca Biopharma Inc (NASDAQ:ABIO) announced its quarterly earnings results on Monday, May, 15th. The company reported ($0.48) EPS for the quarter. View Arca Biopharma's Earnings History.

Who are some of Arca Biopharma's key competitors?

Some companies that are related to Arca Biopharma include Cleveland BioLabs (CBLI), Trillium Therapeutics (TRIL), Nivalis Therapeutics (NVLS), Chiasma (CHMA), Histogenics Corp (HSGX), KaloBios Pharmaceuticals (KBIO), Threshold Pharmaceuticals (THLD), Can Fite Biopharma Ltd (CANF), Alcobra Ltd (ADHD), Viking Therapeutics (VKTX), Mirna Therapeutics (MIRN), Catabasis Pharmaceuticals (CATB), Aldeyra Therapeutics (ALDX), Pain Therapeutics (PTIE), Ocera Therapeutics (OCRX), Dimension Therapeutics (DMTX), Marinus Pharmaceuticals (MRNS) and Vical Incorporated (VICL).

How do I buy Arca Biopharma stock?

Shares of Arca Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Arca Biopharma stock cost?

One share of Arca Biopharma stock can currently be purchased for approximately $2.35.

Consensus Ratings for Arca Biopharma (NASDAQ:ABIO) (?)

Ratings Breakdown:	No ratings tracked in the last 12 months.
Consensus Rating:	N/A (Score: NaN)
Consensus Price Target:	N/A

Analysts' Ratings History for Arca Biopharma (NASDAQ:ABIO)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price	Details
2/23/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$5.00 -> $4.00	N/A
2/23/2016	Cowen and Company	Reiterated Rating	Market Perform	$5.50 -> $4.00	N/A

(Data available from 5/27/2015 forward)

Earnings History for Arca Biopharma (NASDAQ:ABIO)

Earnings by Quarter for Arca Biopharma (NASDAQ:ABIO)

Earnings History by Quarter for Arca Biopharma (NASDAQ:ABIO)

Date	Quarter	Actual EPS	Release Link	Conference Call
5/15/2017	Q1 2017	($0.48)	View	N/A
11/14/2016	Q3 2016	($0.51)	View	N/A
8/9/2016	Q216	($0.43)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Arca Biopharma (NASDAQ:ABIO)

Current Year EPS Consensus Estimate: $-1.75 EPS
Next Year EPS Consensus Estimate: $-1.19 EPS

Dividend History for Arca Biopharma (NASDAQ:ABIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Arca Biopharma (NASDAQ:ABIO)

Insider Ownership Percentage: 2.46%
Institutional Ownership Percentage: 50.54%

Insider Trades by Quarter for Arca Biopharma (NASDAQ:ABIO)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
5/2/2017	Daniel J Mitchell	Director	Buy	11,000	$2.71	$29,810.00
4/4/2017	Christopher David Ozeroff	VP	Sell	418	$2.41	$1,007.38
4/4/2017	Michael R. Bristow	Insider	Sell	720	$2.41	$1,735.20
4/4/2017	Thomas A. Keuer	COO	Sell	390	$2.41	$939.90
4/3/2017	Brian L. Selby	VP	Sell	1,114	$2.46	$2,740.44
3/24/2017	Robert E Conway	Director	Buy	25,000	$2.59	$64,750.00
2/28/2017	Michael R. Bristow	Insider	Sell	763	$2.61	$1,991.43
2/28/2017	Thomas A. Keuer	COO	Sell	465	$2.61	$1,213.65
10/18/2016	Thomas A. Keuer	COO	Sell	483	$2.45	$1,183.35
9/20/2016	Christopher David Ozeroff	VP	Sell	1,185	$2.89	$3,424.65
9/20/2016	Michael R. Bristow	Insider	Sell	1,972	$2.89	$5,699.08
9/20/2016	Thomas A. Keuer	COO	Sell	714	$2.89	$2,063.46
9/19/2016	Brian L. Selby	VP	Sell	476	$2.91	$1,385.16
4/5/2016	Christopher David Ozeroff	VP	Sell	366	$3.52	$1,288.32
4/5/2016	Michael R Bristow	Insider	Sell	724	$3.52	$2,548.48
4/5/2016	Thomas A Keuer	COO	Sell	384	$3.52	$1,351.68
4/4/2016	Brian L Selby	VP	Sell	1,114	$3.52	$3,921.28
3/1/2016	Christopher David Ozeroff	VP	Sell	458	$3.51	$1,607.58
3/1/2016	Michael R. Bristow	Insider	Sell	752	$3.50	$2,632.00
3/1/2016	Thomas A. Keuer	COO	Sell	457	$3.53	$1,613.21
9/18/2015	Christopher David Ozeroff	VP	Sell	1,129	$6.32	$7,135.28
3/2/2015	Brian L Selby	VP	Sell	1,125	$0.71	$798.75
3/2/2015	Michael R Bristow	Insider	Sell	5,446	$0.71	$3,866.66
1/16/2015	Riley Mccormack	Major Shareholder	Sell	350,000	$0.76	$266,000.00
1/7/2015	Riley Mccormack	Major Shareholder	Sell	550,000	$0.92	$506,000.00
9/18/2014	Michael R Bristow	CEO	Sell	13,853	$1.30	$18,008.90
9/18/2014	Patrick M Wheeler	CFO	Sell	8,246	$1.31	$10,802.26
2/4/2014	Riley Mccormack	Major Shareholder	Buy	1,000,000	$1.70	$1,700,000.00

(Data available from 1/1/2013 forward)

Headline Trends for Arca Biopharma (NASDAQ:ABIO) Latest Headlines for Arca Biopharma (NASDAQ:ABIO)

Source:

Date	Headline
	Arca Biopharma Inc (ABIO) Releases Quarterly Earnings Results www.americanbankingnews.com - May 16 at 1:10 PM
	BRIEF-ARCA Biopharma Q1 loss per share $0.48 www.reuters.com - May 15 at 3:15 PM
	ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update finance.yahoo.com - May 15 at 3:15 PM
	Daniel J. Mitchell Buys 11,000 Shares of Arca Biopharma Inc (ABIO) Stock www.americanbankingnews.com - May 4 at 1:26 AM
	Arca Biopharma (ABIO) Receives News Sentiment Rating of 0.56 www.americanbankingnews.com - May 3 at 8:28 AM
	Somewhat Positive Press Coverage Likely to Affect Arca Biopharma (ABIO) Share Price www.americanbankingnews.com - April 27 at 2:04 PM
	BRIEF-Arca Biopharma Inc files for mixed shelf of up to $75 mln www.businessinsider.com - April 27 at 1:26 AM
	ARCA biopharma Announces 200th Patient Randomized into the GENETIC-AF Seamless Design Phase 2B/3 Clinical Trial finance.yahoo.com - April 26 at 3:24 PM
	Favorable News Coverage Extremely Likely to Affect Arca Biopharma (ABIO) Stock Price www.americanbankingnews.com - April 22 at 9:15 AM
	ARCA biopharma to Present at the Planet MicroCap Showcase 2017 Investor Conference finance.yahoo.com - April 18 at 3:15 PM
	Arca Biopharma Inc (ABIO) Director Purchases $64,750.00 in Stock www.americanbankingnews.com - March 27 at 10:48 PM
	FDA Nod For Parkinson's Drug, ABIO Awaits Data In Q3, Busy Year Ahead For VKTX www.rttnews.com - March 22 at 3:17 PM
	ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update www.businesswire.com - March 21 at 8:22 PM
	NOVN Moves Ahead, PTCT Finally Achieves It, TGTX Gets GENUINE Reaction www.rttnews.com - March 7 at 3:15 PM
	ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial finance.yahoo.com - March 6 at 8:56 AM
	ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers biz.yahoo.com - March 1 at 8:16 PM
	Anders Hove, M.D. (Photo: Business Wire) www.thestreet.com - February 21 at 3:32 PM
	Anders Hove, MD Joins ARCA biopharma Board of Directors finance.yahoo.com - February 21 at 3:32 PM
	ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits biz.yahoo.com - February 21 at 3:32 PM
	ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial finance.yahoo.com - January 18 at 3:39 PM
	ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit biz.yahoo.com - January 11 at 8:17 PM
	ARCA biopharma to Present at Biotech Showcase 2017 finance.yahoo.com - January 4 at 3:17 PM
	StockNewsNow.com Publishes New SNNLive Video Interview with ARCA biopharma, Inc. Provides Company Overview and Discusses Clinical Development finance.yahoo.com - November 15 at 12:32 PM
	ARCA biopharma Announces Third Quarter 2016 Financial Results and Provides Business Update www.businesswire.com - November 14 at 8:55 PM
	BRIEF-Arca Biopharma Q3 loss per share $0.51 www.reuters.com - November 14 at 8:55 PM
	Dr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc. www.thestreet.com - October 7 at 8:02 AM
	ARCA biopharma to Present at the Dawson James Securities Second Annual Growth Stock Conference finance.yahoo.com - October 4 at 3:15 PM
	ARCA biopharma Named Winner of Corporate LiveWire Healthcare and Lifesciences Innovation Award finance.yahoo.com - September 13 at 3:15 PM
	EARS Faces The Music, ABIO On Track, TEVA Gets EU Nod For Asthma Drug www.rttnews.com - August 19 at 11:29 AM
	BRIEF-Arca says 100th patient randomized into the genetic-AF phase 2b/3 clinical trial www.reuters.com - August 18 at 3:15 PM
	Form 4 ARCA biopharma, Inc. For: Jun 09 Filed by: Selby Brian L. www.streetinsider.com - June 15 at 3:16 PM
	ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote o biz.yahoo.com - June 13 at 5:01 PM
	ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update - Business Wire (press release) www.businesswire.com - May 12 at 9:47 AM
	ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report biz.yahoo.com - May 11 at 4:49 PM
	ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits biz.yahoo.com - April 18 at 4:31 PM
	ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial - Business Wire (press release) www.businesswire.com - April 18 at 10:27 AM
	ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial finance.yahoo.com - April 18 at 9:00 AM
	ARCA BIOPHARMA, INC. Financials finance.yahoo.com - March 23 at 1:04 PM
	ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi biz.yahoo.com - March 17 at 4:44 PM
	GENETIC-AF Clinical Trial for Prevention of Atrial Fibrillation Enrolls 50th Patient finance.yahoo.com - January 12 at 8:30 AM
	Applying Lessons from KBIO finance.yahoo.com - December 8 at 9:00 AM
	2 Micro-Cap Opportunities in Atrial Fibrillation finance.yahoo.com - November 30 at 9:38 AM
	Biotechs Under 20 Dollars Poised to Breakout finance.yahoo.com - November 23 at 3:07 PM